FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4250369940> ?p ?o ?g. }

• W4250369940 endingPage "4095" @default.
• W4250369940 startingPage "4086" @default.
• W4250369940 abstract "The expression of P-glycoprotein (Pgp) is often increased in acute myeloid leukemia (AML). However, little is known of the regulation of Pgp expression by cytotoxics in AML. We examined whether Pgp expression and function in leukemic blasts was altered after a short exposure to cytotoxics. Blasts were isolated from 19 patients with AML (15 patients) or chronic myeloid leukemia in blastic transformation (BT-CML, 4 patients). Pgp expression and function were analyzed by flow cytometric analysis of MRK 16 binding and Rhodamine 123 retention, respectively. At equitoxic concentrations, ex vivo exposure for 16 hours to the anthracyclines epirubicin (EPI), daunomycin (DAU), idarubicin (IDA), or MX2 or the nucleoside analogue cytosine arabinoside (AraC) differentially upregulated MDR1/Pgp expression in Pgp-negative and Pgp-positive blast cells. In Pgp-negative blasts, all four anthracyclines and AraC significantly increased Pgp expression (P = .01) and Pgp function (P = .03). In contrast, MX2, DAU, and AraC were the most potent in inducing Pgp expression and function in Pgp positive blasts (P < .05). A good correlation between increased Pgp expression and function was observed in Pgp-negative (r = .90, P = .0001) and Pgp-positive blasts (r = .77,P = .0002). This increase in Pgp expression and function was inhibited by the addition of 1 μmol/L PSC 833 to blast cells at the time of their exposure to these cytotoxics. In 1 patient with AML, an increase in Pgp levels was observed in vivo at 4 and 16 hours after the administration of standard chemotherapy with DAU/AraC. Upregulation of Pgp expression was also demonstrated ex vivo in blasts harvested from this patient before the commencement of treatment. In 3 other cases (1 patient with AML and 2 with BT-CML) in which blasts were Pgp negative at the time of initial clinical presentation, serial samples at 1 to 5 months after chemotherapy showed the presence of Pgp-positive blasts. All 3 patients had refractory disease. Interestingly, in all 3 cases, upregulation of Pgp by cytotoxics was demonstrated ex vivo in blasts harvested at the time of presentation. These data suggest that upregulation of the MDR1 gene may represent a normal response of leukemic cells to cytotoxic stress and may contribute to clinical drug resistance." @default.
• W4250369940 created "2022-05-12" @default.
• W4250369940 creator A5004548801 @default.
• W4250369940 creator A5008173055 @default.
• W4250369940 creator A5019296785 @default.
• W4250369940 creator A5037624994 @default.
• W4250369940 creator A5045578819 @default.
• W4250369940 creator A5052587383 @default.
• W4250369940 creator A5060469120 @default.
• W4250369940 creator A5062242214 @default.
• W4250369940 creator A5086617742 @default.
• W4250369940 date "1999-06-15" @default.
• W4250369940 modified "2023-09-27" @default.
• W4250369940 title "Altered Multidrug Resistance Phenotype Caused by Anthracycline Analogues and Cytosine Arabinoside in Myeloid Leukemia" @default.
• W4250369940 cites W102345969 @default.
• W4250369940 cites W109239621 @default.
• W4250369940 cites W1518457310 @default.
• W4250369940 cites W1538763799 @default.
• W4250369940 cites W1598432003 @default.
• W4250369940 cites W1969158591 @default.
• W4250369940 cites W1970161839 @default.
• W4250369940 cites W1973148046 @default.
• W4250369940 cites W1986559713 @default.
• W4250369940 cites W1989008981 @default.
• W4250369940 cites W1991616331 @default.
• W4250369940 cites W1992519649 @default.
• W4250369940 cites W2001237845 @default.
• W4250369940 cites W2009396840 @default.
• W4250369940 cites W2010579436 @default.
• W4250369940 cites W2012927537 @default.
• W4250369940 cites W2019044456 @default.
• W4250369940 cites W2019386320 @default.
• W4250369940 cites W2022406699 @default.
• W4250369940 cites W2029014224 @default.
• W4250369940 cites W2036009804 @default.
• W4250369940 cites W2039068269 @default.
• W4250369940 cites W2047248462 @default.
• W4250369940 cites W2049564631 @default.
• W4250369940 cites W2062933650 @default.
• W4250369940 cites W2063545427 @default.
• W4250369940 cites W2074899375 @default.
• W4250369940 cites W2075450798 @default.
• W4250369940 cites W2078317923 @default.
• W4250369940 cites W2079401403 @default.
• W4250369940 cites W2088060636 @default.
• W4250369940 cites W2088759826 @default.
• W4250369940 cites W2091753012 @default.
• W4250369940 cites W2136648921 @default.
• W4250369940 cites W2138138876 @default.
• W4250369940 cites W2147524358 @default.
• W4250369940 cites W2156515223 @default.
• W4250369940 cites W2162097287 @default.
• W4250369940 cites W2167564928 @default.
• W4250369940 cites W2288226674 @default.
• W4250369940 cites W2404356933 @default.
• W4250369940 cites W296088407 @default.
• W4250369940 cites W4250427149 @default.
• W4250369940 cites W4254298633 @default.
• W4250369940 cites W70444494 @default.
• W4250369940 doi "https://doi.org/10.1182/blood.v93.12.4086.412k43_4086_4095" @default.
• W4250369940 hasPublicationYear "1999" @default.
• W4250369940 type Work @default.
• W4250369940 citedByCount "3" @default.
• W4250369940 crossrefType "journal-article" @default.
• W4250369940 hasAuthorship W4250369940A5004548801 @default.
• W4250369940 hasAuthorship W4250369940A5008173055 @default.
• W4250369940 hasAuthorship W4250369940A5019296785 @default.
• W4250369940 hasAuthorship W4250369940A5037624994 @default.
• W4250369940 hasAuthorship W4250369940A5045578819 @default.
• W4250369940 hasAuthorship W4250369940A5052587383 @default.
• W4250369940 hasAuthorship W4250369940A5060469120 @default.
• W4250369940 hasAuthorship W4250369940A5062242214 @default.
• W4250369940 hasAuthorship W4250369940A5086617742 @default.
• W4250369940 hasConcept C114851261 @default.
• W4250369940 hasConcept C121608353 @default.
• W4250369940 hasConcept C133936738 @default.
• W4250369940 hasConcept C203014093 @default.
• W4250369940 hasConcept C207001950 @default.
• W4250369940 hasConcept C2776802502 @default.
• W4250369940 hasConcept C2778041864 @default.
• W4250369940 hasConcept C2778461978 @default.
• W4250369940 hasConcept C2778589691 @default.
• W4250369940 hasConcept C2778707650 @default.
• W4250369940 hasConcept C2778729363 @default.
• W4250369940 hasConcept C2779117419 @default.
• W4250369940 hasConcept C2779282312 @default.
• W4250369940 hasConcept C2780847677 @default.
• W4250369940 hasConcept C2781021840 @default.
• W4250369940 hasConcept C502942594 @default.
• W4250369940 hasConcept C530470458 @default.
• W4250369940 hasConcept C54355233 @default.
• W4250369940 hasConcept C86803240 @default.
• W4250369940 hasConcept C89423630 @default.
• W4250369940 hasConcept C98274493 @default.
• W4250369940 hasConceptScore W4250369940C114851261 @default.
• W4250369940 hasConceptScore W4250369940C121608353 @default.
• W4250369940 hasConceptScore W4250369940C133936738 @default.
• W4250369940 hasConceptScore W4250369940C203014093 @default.

• next